Follow the people · Insider
Teresa Brophy Bair
Teresa Brophy Bair files insider transactions with the SEC as a chief legal officer of Kura Oncology (KURA). We hold 3 disclosed purchases and sales filed since 7 August 2020, 1 of them in the last 90 days.
- Files forKURA
- Disclosed buys and sells3 in all, 1 in the last 90 days
- Last disclosure21 August 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 18 October 2021 — 19 August 2026Chief Legal Officer · Kura Oncology (KURA)29 Form 4 lines · source: SEC Form 4
- Filed 5 August 2020 — 3 August 2021General Counsel, SVP Admin. · Athenex (ATNX)4 Form 4 lines · source: SEC Form 4
Everything they disclosed
33 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 31,487 shares of Kura OncologySEC Form 421 August 2026Common Stock · traded 19 August 2026 · filed 21 August 2026
- ▼ sold on the open market 2,256 shares of Kura OncologySEC Form 420 May 2026Common Stock · traded 18 May 2026 · filed 20 May 2026
- ▼ sold on the open market 4,096 shares of Kura OncologySEC Form 427 January 2026Common Stock · traded 27 January 2026 · filed 27 January 2026
- ▼ sold on the open market 2,335 shares of Kura OncologySEC Form 427 January 2026Common Stock · traded 27 January 2026 · filed 27 January 2026
- ▼ sold on the open market 4,777 shares of Kura OncologySEC Form 427 January 2026Common Stock · traded 27 January 2026 · filed 27 January 2026
- ▼ sold on the open market 4,096 shares of Kura OncologySEC Form 427 January 2026Common Stock · traded 27 January 2026 · filed 27 January 2026
- ▼ sold on the open market 2,335 shares of Kura OncologySEC Form 427 January 2026Common Stock · traded 27 January 2026 · filed 27 January 2026
- ▼ sold on the open market 4,777 shares of Kura OncologySEC Form 427 January 2026Common Stock · traded 27 January 2026 · filed 27 January 2026
- was granted 50,000 shares of Kura OncologySEC Form 46 January 2026Common Stock · traded 2 January 2026 · filed 6 January 2026
- was granted 100,000 shares of Kura Oncology (a derivative holding)SEC Form 46 January 2026Option to purchase common stock · traded 2 January 2026 · filed 6 January 2026
- was granted 100,000 shares of Kura Oncology (a derivative holding)SEC Form 46 January 2026Option to purchase common stock · traded 2 January 2026 · filed 6 January 2026
- was granted 50,000 shares of Kura OncologySEC Form 46 January 2026Common Stock · traded 2 January 2026 · filed 6 January 2026
- was granted 48,900 shares of Kura OncologySEC Form 414 November 2025Common Stock · traded 13 November 2025 · filed 14 November 2025
- ▼ sold on the open market 8,804 shares of Kura OncologySEC Form 414 November 2025Common Stock · traded 14 November 2025 · filed 14 November 2025
- was granted 48,900 shares of Kura OncologySEC Form 429 September 2025Common Stock · traded 27 September 2025 · filed 29 September 2025
- ▼ sold on the open market 8,805 shares of Kura OncologySEC Form 429 September 2025Common Stock · traded 29 September 2025 · filed 29 September 2025
- ▼ sold on the open market 1,559 shares of Kura OncologySEC Form 419 May 2025Common Stock · traded 19 May 2025 · filed 19 May 2025
- ▼ sold on the open market 2,437 shares of Kura OncologySEC Form 428 January 2025Common Stock · traded 28 January 2025 · filed 28 January 2025
- ▼ sold on the open market 4,844 shares of Kura OncologySEC Form 428 January 2025Common Stock · traded 28 January 2025 · filed 28 January 2025
- was granted 92,500 shares of Kura Oncology (a derivative holding)SEC Form 46 January 2025Option to purchase common stock · traded 2 January 2025 · filed 6 January 2025
- was granted 46,250 shares of Kura OncologySEC Form 46 January 2025Common Stock · traded 2 January 2025 · filed 6 January 2025
- ▼ sold on the open market 2,615 shares of Kura OncologySEC Form 420 May 2024Common Stock · traded 20 May 2024 · filed 20 May 2024
- ▼ sold on the open market 2,053 shares of Kura OncologySEC Form 431 January 2024Common Stock · traded 29 January 2024 · filed 31 January 2024
- was granted 92,500 shares of Kura Oncology (a derivative holding)SEC Form 44 January 2024Option to purchase common stock · traded 2 January 2024 · filed 4 January 2024
- was granted 46,250 shares of Kura OncologySEC Form 44 January 2024Common Stock · traded 2 January 2024 · filed 4 January 2024
- was granted 138,750 shares of Kura Oncology (a derivative holding)SEC Form 421 February 2023Option to purchase common stock · traded 16 February 2023 · filed 21 February 2023
- was granted 23,125 shares of Kura OncologySEC Form 421 February 2023Common Stock · traded 16 February 2023 · filed 21 February 2023
- ▼ sold on the open market 2,100 shares of Kura OncologySEC Form 418 November 2022Common Stock · traded 17 November 2022 · filed 18 November 2022
- was granted 192,000 shares of Kura Oncology (a derivative holding)SEC Form 419 October 2021Option to purchase common stock · traded 18 October 2021 · filed 19 October 2021
- was granted 37,500 shares of Athenex (a derivative holding)SEC Form 45 August 2021Stock Option (Right to Buy) · traded 3 August 2021 · filed 5 August 2021
- was granted 37,500 shares of Athenex (a derivative holding)SEC Form 45 August 2021Restricted Stock Units · traded 3 August 2021 · filed 5 August 2021
- was granted 15,000 shares of Athenex (a derivative holding)SEC Form 431 August 2020Stock Option (Right to Buy) · traded 27 August 2020 · filed 31 August 2020
- was granted 60,000 shares of Athenex (a derivative holding)SEC Form 47 August 2020Stock Option (Right to Buy) · traded 5 August 2020 · filed 7 August 2020
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.